UK markets open in 5 hours 14 minutes
  • NIKKEI 225

    +82.58 (+0.28%)

    +405.61 (+1.39%)

    +0.18 (+0.30%)

    -2.40 (-0.14%)
  • DOW

    -143.99 (-0.46%)

    -397.12 (-1.12%)
  • CMC Crypto 200

    -8.25 (-0.84%)
  • ^IXIC

    -230.04 (-1.69%)
  • ^FTAS

    +10.23 (+0.27%)

Global Autoinjectors Market By Type, By Application, By End Use, By Region, Industry Analysis and Forecast, 2020 - 2026

·7-min read

The Global Autoinjectors Market size is expected to reach $5. 3 billion by 2026, rising at a market growth of 17. 6% CAGR during the forecast period. An autoinjector is a medical device consist of a syringe having a spring-charged needle containing a pre-charged dosage of drugs and is designed to administer a dose of a specific drug.

New York, Feb. 08, 2021 (GLOBE NEWSWIRE) -- announces the release of the report "Global Autoinjectors Market By Type, By Application, By End Use, By Region, Industry Analysis and Forecast, 2020 - 2026" -
These injectors were primarily designed to overcome the fear related to the needle-based drug delivery device used for self-administration.

The system activates and administers a measured amount of a drug when pushed into the body of the subject with a downward motion. Autoinjectors are extensively used for self-administration of epinephrine in order to prevent anaphylaxis. Epinephrine is taken by migraine sufferers to get immediate pain relief and also for other medical emergency treatments. Auto-injectors have multiple benefits including reducing needle-related phobia disorder, decreases the risks of needle jammed accidents, make sure dosage quality steadiness, and serving increase effectiveness.

The auto-injector market is likely to register considerable growth in the coming years, due to increased cases of anaphylaxis. In addition to it, there is a rapid rise in R&D efforts by manufacturing companies. These efforts are in direction to develop simple, cost-effective, and novel technology-based autoinjectors that can be used for the treatment of chronic diseases including rheumatoid arthritis and multiple sclerosis. Such developments are anticipated to drive the market growth during the forecast period.

By Type

Based on Type, the market is segmented into Disposable autoinjectors and Reusable autoinjectors. The disposable autoinjectors segment had the largest share of the global market of autoinjectors in 2019. Disposable autoinjectors are preferred mostly owing to their ease of use and also the presence of the built-in glass syringe eliminates the necessity of manually filling the glass syringe, which makes it more suitable for patients with visual impairments or reduced dexterity.

By Application

Based on Application, the market is segmented into Anaphylaxis, Rheumatoid Arthritis, Multiple Sclerosis and other Applications. In 2019, Anaphylaxis segment had the largest share of the autoinjectors market. This is mainly accredited to its high occurrence. The growing incidence of rheumatoid arthritis also drives the demand for autoinjectors worldwide. As per the CDC, around 43.7 million adults which comprise 22.7% of the total population of the US are affected by some form of arthritis such as RA, lupus, gout, or fibromyalgia annually.

By End Use

Based on End Use, the market is segmented into Hospitals & Clinics and Home care settings. The hospital segment is expected to grow at faster pace in the coming years due to a surge in the number of patients who are suffering from multiple sclerosis and anaphylaxis. Multiple sclerosis is very common in the U.S., Europe, Canada, and New Zealand. It affects more than 400,000 people alone in the U.S. and about 2.5 million people all across the globe.

By Region

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. The growth of the market in the Asia Pacific market is largely due to the large number of patients suffering from chronic allergies and diabetes as well as increasing healthcare expenditure. This in turn has drawn a number of key auto-injector device manufacturers to this region. These companies are showing more presence in the Asia Pacific market via several approaches, including partnering with local pharmaceutical companies and establishing sales offices. The growing occurrence of type 1 diabetes is expected to drive market growth.

The major strategies followed by the market participants are Product Launches and Partnerships. Based on the Analysis presented in the Cardinal matrix; Amgen, Inc., Biogen, Inc., and GlaxoSmithKline PLC, Company are the forerunners in the Auto-Injectors Market. Companies such as Sanofi S.A., Teva Pharmaceuticals Industries Ltd., Becton, Dickinson and Company, Ypsomed AG, and Merck Group are some of the key innovators in the market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly and Company, GlaxoSmithKline PLC (GSK), Merck Group, Sanofi S.A., Becton, Dickinson and Company, Teva Pharmaceuticals Industries Ltd., Amgen, Inc., Ypsomed AG, AbbVie, Inc. and Biogen, Inc.

Strategies deployed in Auto-Injectors Market

Partnerships, Collaborations, and Agreements:

Nov-2020: Eli Lilly signed an agreement with Ypsomed. The agreement aimed to advance an automated insulin delivery system as a part of Lilly’s connected diabetes solution. Under this agreement, Lilly commercialized the system that includes an insulin pump developed and manufactured by Ypsomed.

Jun-2020: Teva collaborated with Schreiner MediPharm. The collaboration aims to develop an Auto injector-Label with special protection against abrasion for the allergy emergency drug epinephrine from Teva. The label developed by Schreiner MediPharm for Teva’s adrenaline injector provided with abrasion- and scratch-resistant reverse printing.

Jul-2019: Teva Pharmaceutical collaborated with Ypsomed. The companies together introduced the drug product Copaxone, which is used for the treatment of patients with relapsing forms of multiple sclerosis.

Jun-2019: Sanofi entered into a partnership with Enable Injections. The partnership aimed to include multiple molecule development programs incorporating long-term manufacturing and supply arrangements.

Jun-2018: AbbVie teamed up with Eisai. The companies aimed to launch the autoinjection delivery system for HUMIRA. HUMIRA, a pen-type auto-injector device developed to simplify the operation and reduce the burden on patients when performing self-injection.

Jan-2018: Biogen collaborated with Eisai. The collaboration focused on the promotion of Biogen’s multiple sclerosis treatments TECFIDERA, TYSABRI, and AVONEX in Japan.

Product Launches and Product Expansions:

Oct-2020: Sanofi introduced Tetraxim, a new booster vaccine. This booster vaccine combined four vaccines for reducing the number of injections, increasing comfort, and enhancing vaccination compliance for children. Tetraxim is indicated for preschoolers and offers protection against four major diseases namely diphtheria, pertussis, tetanus, and polio.

Apr-2020: Teva Pharmaceuticals launched the auto-injector device for AJOVY injection in the U.S. AJOVY indicated the preventive treatment of migraine in adults and the only anti-CGRP preventive migraine treatment with quarterly and monthly subcutaneous dosing options.

Oct-2019: Becton, Dickinson, and Company introduced the BD Intevi 1mL two-step disposable auto-injector. The auto-injector is a two-step push-on-skin device that is designed to effectively and safely inject various drugs of different viscosities up to 35cP and different fill volumes up to 1mL.

Aug-2019: Teva Pharmaceutical launched an FDA-approved generic version of EpiPen Jr 1 Auto-Injector, 0.15 mg, in the U.S.


Jan-2020: Sanofi got the approval of a 300 mg single-dose pre-filled pen for Dupixent by the U.S. Food and Drug Administration. The new pre-filled pen provided patients with a more convenient option for administering Dupixent.

Jan-2020: Teva Pharmaceutical received approval from the U.S. Food and Drug Administration for Ajovy, an auto-injector for its migraine-treatment drug.

Jun-2019: GlaxoSmithKline got approval from the US Food and Drug Administration (FDA) for two new methods for administering Nucala (mepolizumab). Nucala is an auto-injector and a pre-filled safety syringe, for patients or caregivers to administer once every four weeks, after discussing it with healthcare professionals.

Scope of the Study

Market Segments covered in the Report:

By Type

• Disposable autoinjectors

• Reusable autoinjectors

By Application

• Anaphylaxis

• Rheumatoid Arthritis

• Multiple Sclerosis

• Other Applications

By End Use

• Hospitals & Clinics

• Home care settings

By Geography

• North America

o US

o Canada

o Mexico

o Rest of North America

• Europe

o Germany

o UK

o France

o Russia

o Spain

o Italy

o Rest of Europe

• Asia Pacific

o China

o Japan

o India

o South Korea

o Singapore

o Malaysia

o Rest of Asia Pacific


o Brazil

o Argentina


o Saudi Arabia

o South Africa

o Nigeria

o Rest of LAMEA

Companies Profiled

• Eli Lilly and Company

• GlaxoSmithKline PLC (GSK)

• Merck Group

• Sanofi S.A.

• Becton, Dickinson and Company

• Teva Pharmaceuticals Industries Ltd.

• Amgen, Inc.

• Ypsomed AG

• AbbVie, Inc.

• Biogen, Inc.

Unique Offerings

• Exhaustive coverage

• Highest number of market tables and figures

• Subscription based model available

• Guaranteed best price

• Assured post sales research support with 10% customization free
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.


CONTACT: Clare: US: (339)-368-6001 Intl: +1 339-368-6001